ストックスクリーナーアプリを入手
1.74
1.75%
0.03
Invivyd Inc (IVVD) 最新ニュース
Invivyd rises after update from late-stage trial for COVID therapy - MSN
Invivyd stock surges as FDA alignment boosts COVID-19 program - MSN
Aug Reactions: What are Invivyd Incs technical support levelsLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is (NASDAQ:IVVD) - Seeking Alpha
Authentic virus research in labs faces adaptation hurdles, Invivyd, Inc. asserts - Traders Union
Invivyd unveils measles monoclonal antibody candidate VMS-063 - BioWorld News
H.C. Wainwright reiterates Invivyd stock rating on measles program By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Invivyd stock rating on measles program - Investing.com
Invivyd upsizes COVID-19 trial, targets measles antibody By Investing.com - Investing.com Australia
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody CandidateSlideshow (NASDAQ:IVVD) 2026-04-09 - Seeking Alpha
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 - MarketBeat
Invivyd stock surges 25% on COVID-19 trial progress By Investing.com - Investing.com Australia
Invivyd reveals plans to test an antibody drug against measles - BioPharma Dive
Invivyd posts update from late-stage COVID trial (IVVD:NASDAQ) - Seeking Alpha
Invivyd stock surges 25% on COVID-19 trial progress - Investing.com
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 ProgramInvivyd (NASDAQ:IVVD) - Benzinga
Invivyd Advances COVID-19 and Measles Monoclonal Antibody Programs With Phase 3 Updates and New VMS063 Candidate for Measles Prevention and Treatment 1 - Minichart
Invivyd Advances COVID-19 Program and Launches Measles Antibody - TipRanks
Invivyd upsizes DECLARATION Phase 3, delays topline to Q3 2026; advances measles mAb VMS063 toward IND - TradingView
Invivyd upsizes COVID-19 trial, targets measles antibody - Investing.com
Invivyd (IVVD) expands VYD2311 Phase 3 and pushes potent measles antibody VMS063 toward clinic - Stock Titan
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles - The Manila Times
Invivyd, Inc. outlines antibody response as critical for immune defense actions - Traders Union
Surprises Report: What makes Invivyd Inc stock attractive todayQuarterly Portfolio Review & Low Risk Entry Point Guides - baoquankhu1.vn
Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health - Bitget
Invivyd Launches 'Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health - The Manila Times
Lindsey Vonn joins Invivyd's antibody education campaign - Stock Titan
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates - MSN
Invivyd (NASDAQ: IVVD) plans 2026 virtual meeting and auditor vote - Stock Titan
IVVD Technical Analysis & Stock Price Forecast - Intellectia AI
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Invivyd Announces Presentation at the World Vaccine Congress Washington - manilatimes.net
Invivyd Inc. (IVVD) Stock Price Quote Today & Current Price Chart - Capital.com
Joel Greenblatt's Invivyd Inc(IVVD) Holding History - gurufocus.com
At vaccine congress, Invivyd says antibody drugs can track viral shifts - Stock Titan
Investment Recap: What makes Invivyd Inc stock attractive today2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
2.19%
0.43%
大文字化:
|
ボリューム (24 時間):